The New England Journal of Medicine is investigating allegations of research misconduct in a key study used to approve Amgen ...

Amgen stock snapshot and recent performance Amgen (AMGN) is drawing attention after recent price moves, with the stock last ...

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Amgen (NASDAQ:AMGN) executives used a Jefferies investor ...

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. Amgen Inc. (NASDAQ:AMGN) announced on June 1 ...

Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. What do Amgen, Biogen, and ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, ​citing a lack of proven ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.